ArticleEuropean journal of nuclear medicine and molecular imaging2026
Cranial glucose metabolic patterns across prodromal and clinical parkinson's disease revealed by
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBone plays pivotal roles in glucose homeostasis of the human body. Parkinson's disease (PD) is accompanied by metabolic dysfunction and increased risks of bone diseases. Nevertheless, whether PD affects bone glucose metabolism remains unknown. This study aimed to assess cranial glucose metabolism in different stages of PD using brain
methodsThis prospective cross-sectional study included 190 participants, including 34 controls, 32 prodromal PD (pPD), 50 de novo PD (dnPD) and 74 medicated PD (mPD) patients. mPD patients were further separated into 3 stages: early-, middle- and late-stage PD patients. Comparisons of glucose uptake in the cranium was assessed using general linear model among controls, pPD, dnPD and mPD patients, as well as among mPD patients with different stages. Furthermore, effects of motor function, disease duration and dopaminergic medication on cranial glucose uptake were assessed using multiple linear regression.
resultsThe results demonstrated cranial hypermetabolism in clinically confirmed PD patients (dnPD and mPD patients) compared to HCs in the cranium, frontal, sphenoid and parietal bones (p < 0.05). In addition, mPD patients also demonstrated hypermetabolism in temporal and occipital bones compared to HCs (p < 0.05). However, this metabolic pattern was not observed in the prodromal individuals. Moreover, multiple linear regression identified fasting blood glucose as a positive modulator (β = 0.020 ~ 0.043, p < 0.05) and dopaminergic medication as a negative regulator (β=-1.207 × 10
conclusionThe current study uncovered cranial metabolic abnormalities in PD, offering new perspectives and pathophysiological insights underlying bone-related comorbidities in PD.
Indexed as
Identifiers
40900316What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.